XML 54 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1

Revenues (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

						Year ended December 31, 2021																		Year ended December 31, 2020																		Year ended December 31, 2019
						U.S.						ROW						Total						U.S.						ROW						Total						U.S.						ROW						Total
Enbrel						$	4,352					$	113					$	4,465					$	4,855					$	141					$	4,996					$	5,050					$	176					$	5,226
Prolia						2,150						1,098						3,248						1,830						933						2,763						1,772						900						2,672
Otezla(1)						1,804						445						2,249						1,790						405						2,195						139						39						178
XGEVA						1,434						584						2,018						1,405						494						1,899						1,457						478						1,935
Neulasta						1,514						220						1,734						2,001						292						2,293						2,814						407						3,221
Aranesp						537						943						1,480						629						939						1,568						758						971						1,729
Repatha						557						560						1,117						459						428						887						376						285						661
KYPROLIS						736						372						1,108						710						355						1,065						654						390						1,044
Nplate						566						461						1,027						485						365						850						480						315						795
Other products						3,636						2,215						5,851						3,821						1,903						5,724						3,031						1,712						4,743
Total product sales(2)						17,286						7,011						24,297						17,985						6,255						24,240						16,531						5,673						22,204
Other revenues						908						774						1,682						511						673						1,184						693						465						1,158
Total revenues						$	18,194					$	7,785					$	25,979					$	18,496					$	6,928					$	25,424					$	17,224					$	6,138					$	23,362

____________

(1)    Otezla was acquired on November 21, 2019.

(2)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2021, 2020 and 2019.

Revenues earned from major customers

Certain information with respect to these customers was as follows (dollar amounts in millions):

			Years ended December 31,
			2021						2020						2019
McKesson Corporation:
Gross product sales			$	15,187					$	13,779					$	11,795
% of total gross revenues			33		%				32		%				31		%
AmerisourceBergen Corporation:
Gross product sales			$	14,783					$	14,743					$	12,301
% of total gross revenues			32		%				34		%				33		%
Cardinal Health, Inc.:
Gross product sales			$	7,681					$	7,332					$	6,538
% of total gross revenues			17		%				17		%				17		%

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration